A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022. Among the related exchange traded funds, the VanEck Vectors Biotech ETF (BBH), which is one of the bellwethers in this category, is higher by almost 14% since the start of the [...] The post Biotech Rebound Could Finally Be Afoot appeared first on ETF Trends .